3/20/2026Recent Executive Moves

3/20/2026Cloudbreak Pharma Withdraws China IND for CBT-009, Refocuses Ophthalmo...

3/20/2026Kintor Reports Positive Phase III Results for First-in-Class Hair Loss...

3/20/2026Excalipoint Launches With $68.7M Seed to Advance Next-Generation TCE P...

3/20/2026NovaBridge Secures FDA Alignment on Accelerated Pathway for Givastomig...

3/20/2026ELCC 2026: BioKin–Henlius Combo Shows First-Line Promise in ES-SCLC

3/20/2026Alebund Licenses First-in-Class Kidney Drug AP306 to R1 Therapeutics i...

3/20/2026AstraZeneca Expands UK–China Strategy With Cell Therapy R&D Hub and M...

3/17/2026NHSA: China Medical Insurance Revenue Growth Outpaces Spending in 2025

3/17/2026Innorna Wins FDA Clearance to Test mRNA Therapy for Refractory Gout in...

3/17/2026Gyre Thera Liver Fibrosis Drug Receives Priority Review in China

More>>

3/17/2026US Reshoring Push Clouds Long-Term Outlook for China's Contract Drugma...

3/17/2026China to Grant Market and Data Exclusivity for Innovative Drugs for th...

3/13/2026China Private Biotech Financing Slows in February but Larger Deals Sig...

3/12/2026China's Labs Race for the Next First-in-Class Breakthrough

3/10/2026China Challenges High-Priced Gene Therapies with Lower-Cost Alternativ...

3/10/2026China Biotech Dealmaking Defies Seasonal Slowdown as February Licensin...

3/10/2026US Weighs Policy Measures to Address China Biotech Competition

3/9/2026China Biotech Financing Rebounds in Early 2026 as RNA Deals and Global...

3/4/2026China Biotech Outlicensing Surges Past US$52 Billion in Early 2026

3/2/20262026 Biotech Playbook: Hong Kong at the Centre of China's Globalisatio...

2/26/2026China's Healthcare Reform Playbook: Boosting Births and Opening the Do...

More>>